US FDA Approves Yuvezzi, The First Ever Combination Eye Drop For Presbyopia

US FDA Approves Yuvezzi, The First Ever Combination Eye Drop For Presbyopia
US FDA Approves Yuvezzi, The First Ever Combination Eye Drop For Presbyopia
Published on
1 min read

Tenpoint Therapeutics has secured a total of $235 million through a combination of Series B equity financing and a non-dilutive credit facility, strengthening its balance sheet ahead of the commercial launch of YUVEZZI™, its newly approved presbyopia treatment.

The financing includes $85 million raised through a Series B preferred stock round led by Janus Henderson, EQT Nexus, Hillhouse and the British Business Bank. Existing investors, including EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille, also participated. In parallel, the company entered into a $150 million senior secured term loan facility with Hercules Capital.

The funding milestone coincides with the US Food and Drug Administration’s approval of YUVEZZI™, making it the first and only dual-agent, once-daily eye drop approved for the treatment of presbyopia. The product combines carbachol and brimonidine tartrate and is designed to improve near vision while maintaining a favourable safety and tolerability profile.

Tenpoint Therapeutics plans to initiate the commercial launch of YUVEZZI in early Q2 2026, targeting a large and underserved patient population. Presbyopia affects an estimated 128 million people in the United States and nearly 2 billion individuals globally, representing one of the largest unmet needs in ophthalmology.

Headquartered across London and Seattle, Tenpoint operates as a global commercial-stage biotechnology company focused on therapies that rejuvenate vision in the aging eye. The company’s leadership team brings deep ophthalmology expertise, positioning it to execute a full-scale launch and drive adoption across eye care providers.

With regulatory approval secured and financing in place, Tenpoint Therapeutics is advancing its transition into a commercial-stage company, aiming to establish YUVEZZI as a differentiated treatment option in the growing presbyopia market.

Also Read

US FDA Approves Yuvezzi, The First Ever Combination Eye Drop For Presbyopia
Merck Expands India R&D Presence With New Bengaluru Office

Related Stories

No stories found.
Voice Of HealthCare
vohnetwork.com